Voretigene neparvovec-rzyl (Luxturna®) for treatment of biallelic RPE65-related inherited retinal diseases (IRDs) was the first Food and Drug Administration (FDA)-approved ocular gene therapy treatment [1], with subsequent regulatory approval in the UK, Europe, Australia, and other global regions. This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.